Assessing inappropriate medication use in older cardiovascular patients during COVID-19
Official title: Incidence of Prescribing Potentially Inappropriate Medications to Older Cardiovascular Patients During COVID-19 Pandemics According to Medical Information System BARS
Run by Tomsk National Research Medical Center of the Russian Academy of Sciences · NCT05336565 · Data updated 2026-11-12
This study looks at whether older heart patients were given medications that might not be safe for them during the COVID-19 pandemic.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Tomsk National Research Medical Center of the Russian Academy of Sciences Academic / other |
| Locations | 1 site (Tomsk) |
| Status | Recruiting |
| Started | July 1, 2022 |
| Main results expected | August 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | June 24, 2026 |
| Trial ID | NCT05336565 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are cardiovascular patients aged 75 years and older who are enrolled in a reimbursement program in the Tomsk Region.
✕Probably not a fit
Patients under the age of 18 or those without a diagnosis of cardiovascular disease will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the incidence of potentially inappropriate medication (PIM) prescriptions, polypharmacy, and potential drug-drug interactions (PDDIs) among cardiovascular patients aged 75 and older during the COVID-19 pandemic. Utilizing the Medical Information System 'BARS', the study will analyze data from patients enrolled in a reimbursement program in the Tomsk Region. The study will define PIMs based on the 2015 Beers criteria and assess PDDIs using the Medscape Drug Interaction Checker. Both retrospective and prospective data will be combined to provide a comprehensive overview of medication safety in this vulnerable population.
Why it matters
Potential benefit: If successful, this study could enhance patient safety by identifying and reducing the use of inappropriate medications in older cardiovascular patients.
How similar studies have gone: Other studies have shown success in assessing medication safety in older populations, suggesting that this approach is both relevant and necessary.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * established diagnosis of cardiovascular disease * age of 18 years and older * enrollment in the reimbursement program in Tomsk Region Exclusion Criteria: * age of 17 years and younger
Where it's running
-
Tomsk NRMC
Tomsk, Russia Recruiting
Study contacts
- Principal investigator: Nina D Anfinogenova, MD, PhD — Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
- Study coordinator: Nina D Anfinogenova, PhD
- Email: cardio.intl@gmail.com
- Phone: +79095390220
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
e-ALIGN: Using the patient portal to align medicines with what matters most
This project will see if sending education through the patient portal plus pharmacist-led medication reviews helps people 65 and older with mild cognitive impairment or dementia and their care partners reduce risky brain-active medicines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.